|
|
 |
|
Viewing report
|
|
|
|
Advances in RNAi--A Global Technology Assessment (Technical Insights)
Frost & Sullivan, Nov 2004
Transfecting RNAi into Target Cells Proves to be a Significant Challenge
Delivering or transfecting ribonucleic acid interference (RNAi) into mammalian cells is one of the biggest challenges facing researchers. In addition, a tedious optimization process is a prerequisite for the transfection of standard cell lines with commonly used lipofection reagents. Successful delivery of RNAi depends on a few key factors such as the target cell line, RNAi concentration, the ratio of RNAi to the transfection reagent, cell confluence during transfection, and incubation time. Another challenge lies in improving the target specificity of RNAi. In this regard, a well designed RNAi has greater chances of success in targeting the messenger RNA (mRNA) of interest and minimizing off-target effects. In order to test and compare RNAi sequences, researchers need to monitor and optimize RNAi purity and integrity, its uptake, and cell viability.
This research analyzes emerging technologies and applications in RNAi design and delivery. Technological trends, drivers, challenges, and recent developments assist in creating effective marketing and production strategies. Participants can identify potential collaborators, stay ahead of the competition, and keep abreast of critical developments in their industry.
Failure of Related Researches and Technologies Sparks Interest in RNAi Projects
After disappointing results from genomic projects involving antisense technologies and ribozyme projects for gene therapy, researchers are looking at RNAi for a more positive feedback. Since its discovery in 1998, the number of published research papers pertaining to RNAi has skyrocketed from 15 to nearly 1,000 in 2003. The potential this technology holds is amazing, as it provides a new approach to drug discovery, validation, and delivery, amongst other advantages, says the analyst. Given its recent successes in attacking viruses such as HIV, and hepatitis B and C, RNAi holds immense potential for quicker drug delivery. RNAi’s reach is expected to expand in the future, as it attains the capabilities for treating renal and metabolic disorders, and diseases such as cancers and those pertaining to the central nervous system.
RNAi Moves from the Realms of High Throughput Screening to Therapeutics
While RNAi expertise, at present, lies primarily in high-throughput screening (HTS), the technology is set to begin clinical trials and RNAi-based drugs might be a reality by 2010. RNAi therapies that are likely to reach humans first are those targeting macular degeneration, a leading cause of blindness. Caused by over expression of vascular endothelial growth factor (VEGF) in cells in the back of the eye, the disease has several attributes that make it an ideal RNAi showcase, explains the analyst.
Customers who bought this item also bought
Global Advances in Nutraceuticals (Technical Insights)
Antibody Technology Developments (Technical Insights)
Biopharmaceutical Developments--An Emerging Technology Analysis (Technical Insights)
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
Advances in MRI Technologies (Technical Insights)
Advances in Medical Device Technology for Cardiovascular Applications (Technical Insights)
Advances in Medical Device Technology for Orthopaedic Applications (Technical Insights)
Technology Developments in Functional Proteomics (Technical Insights)
|
|
|
|
